DARZALEX FASPRO®
(daratumumab and hyaluronidase-fihj)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
Medical Information
DARZALEX + DARZALEX FASPRO - Adverse Event - Extravasation
Last Updated: 04/17/2024
SUMMARY
- Currently, there are no published reports of extravasation with DARZALEX or DARZALEX FASPRO.
- The Safety Data Sheets for DARZALEX/DARZALEX FASPRO state that the product is non-hazardous based on chemical classification rules. Large protein biotherapeutics in the dry or reconstituted (solution in buffer) forms are not expected to elicit skin corrosion/irritation or skin sensitization.1
, 2 - Daratumumab is neither a vesicant nor an irritant.3
- Consult with your institutional guidelines for management of extravasation.
DARZALEX (daratumumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf - DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf
Literature Search
A literature search of MEDLINE®
02 April 2024 did not identify any relevant citations pertaining to this topic.
References
| 1 | Data on File. DARZALEX FASPRO (daratumumab and hyaluronidase) injection for subcutaneous use - Safety Data Sheet (SDS). Janssen Research & Development, LLC.; 2023. |
| 2 | |
| 3 |